Specifically, in breast cancer (BC) models, upregulation of lnc-SNHG1 in CD4+ TILs promotes their differentiation into Tregs by interacting with miR-448, a negative regulator of indoleamine 2,3-dioxygenase (IDO). This evidence concerns the gene IDO1 and breast cancer.